| Company type | Aktieselskab |
|---|---|
| Industry | Pharmaceuticals, health care[1] |
| Founded | 1958[1] |
| Headquarters | Copenhagen, Denmark[1] |
| Website | http://www.xellia.com |
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen[1] specialized in the production of anti-biotics, including Vancomycin[2] and Bacitracin.[3]
The company's US base of operations is in Buffalo Grove, Illinois,[4][5] with additional facilities in Ohio, and North Carolina.[6][7] In 2018, Xellia's sales in the United States accounted for 60% of its total revenue.[5]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are:[8]
Previously the company also produced:
| Ingredient | Produced |
|---|---|
| Neomycin | 1952-? |
| Tetracycline | 1961-? |
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.[4][19][20][21][22]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.[23]
